Cancer Genetics (NASDAQ:CGIX) Now Covered by

Equities researchers at started coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Rating) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

Cancer Genetics Price Performance

Shares of CGIX stock opened at $4.61 on Monday. The stock has a 50 day simple moving average of $0.77 and a 200-day simple moving average of $0.77. Cancer Genetics has a 12-month low of $2.11 and a 12-month high of $17.50.

Cancer Genetics Company Profile

(Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

See Also

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.